ROIV

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical and healthcare technology company founded in 2014 and headquartered in London, United Kingdom. The company went public in December 2020 and operates as a holding company that develops and commercializes innovative medicines across multiple therapeutic areas. Roivant has built a portfolio of subsidiary companies, each focused on specific drug development programs, and has successfully brought several products to market while maintaining a robust pipeline of clinical-stage assets targeting various diseases including autoimmune disorders, dermatological conditions, and rare diseases.